After signing up, you'll start to receive regular news updates from us.
Applied Biosystems Launches TargetSeq™ Resequencing System
Complete the form below to unlock access to ALL audio articles.
Applied Biosystems, an Applera Corporation business has introduced its TargetSeq™ Resequencing System, a software system for high-throughput directed or medical sequencing designed for use with Applied Biosystems 3730 and 3730xl DNA Analyzers, at the 7th Annual Advancing Genome Biology and Technology (AGBT) Meeting.
The TargetSeq™ Resequencing System features a fast-run software module for the sequencing of individual gene exons or other small DNA fragments.
Applied claims that, TargetSeq™ is able to produce 200 to 400 base pair sequencing reads in 20 minutes or less, increasing the daily production capacity of the 3730 series instruments to 2.8 megabases or 6912 samples (72 runs) per day.
"We expect Applied Biosystem’s TargetSeq™ Resequencing System will have a tremendous impact on our medical sequencing projects where we focus on small, but very important regions of the human genome to identify mutations in complex diseases, such as various cancers," said Kevin J. McKernan, Vice President and Chief Scientist, Agencourt Bioscience Corporation.
"The TargetSeq™ module effectively cuts our machine amortization by more than half and increases our Q40 bases, lowering our overall costs. We now think twice about using sequencing technology which requires 30 times coverage to achieve one-tenth the accuracy."
The number of Q40 bases is a standard measure of the accuracy of DNA base calling results.
According to recent industry data, directed sequencing, also known as medical sequencing, will represent the majority of sequencing projects over the next several years as researchers transition from de novo sequencing to targeted sequencing of coding areas of the human genome.
"We were able to obtain promising data from both our own samples and from controls provided during our testing of the TargetSeq™ Resequencing System," said Chris Clee, Sequencing Facility Manager, The Wellcome Trust Sanger Institute.
"There is also potential to utilize the TargetSeq™ module for one of our large resequencing projects tailored to the 400bp range of products. This will allow us to run more samples in a smaller footprint and free up instruments for longer read requirements."
"The introduction of the TargetSeq™ system into our lab has dramatically increased our throughput on re-sequencing projects, such as those focused on melanoma and prostate cancer. We can now tailor our sequence runs to individual projects," added Steve Mastrian, Assistant Director, DNA Sequencing, Translational Genomics Research Institute (TGen).
The TargetSeq™ Resequencing System also includes a new version of the KB™ Basecaller software optimized for heterozygote/mixed base detection and added flexibility for de novo and directed sequencing applications.
"We are pleased to offer another advance in DNA sequencing based on our gold-standard capillary electrophoresis technology," said Catherine M. Burzik, President, Applied Biosystems.
"As resequencing applications become the primary focus of sequencing work, TargetSeq™ addresses the industry’s need for a more cost-effective, robust, and scalable solution that provides a foundation for the emerging field of personalized medicine."
